Experience the Quality With Free NAPLEX Exam Questions That Helps Candidates Pass

Prescription Drug Monitoring Program (PDMP) review helps identify multiple prescribers, overlapping therapies, and early fills—key for detecting misuse/diversion. Documented PDMP checks, counseling, and prescriber communication align with regulatory guidance and patient safety. Option A may worsen misuse; Option C depends on jurisdiction and still requires appropriate authorization and documentation; partial fills alone do not address root causes. Option D is clinically inappropriate; therapy must be individualized and often de-escalated with risk-mitigation (naloxone co-prescribing, treatment agreements, functional goals). Embedding PDMP in workflow and training staff supports a robust practice model.

The best outcome measure is A1C reduction, which directly correlates with reduced complications. Dispensing counts (A, C) and cost (D) are process or financial metrics, not clinical outcomes. Pharmacist-led interventions are most effective when tied to measurable improvements in glycemic control.

Indinavir, a protease inhibitor, is associated with kidney stones and nephrolithiasis. Patients should be counseled on hydration. Zidovudine causes anemia, efavirenz causes CNS side effects, and lamivudine is generally well-tolerated. Monitoring renal effects is essential in HIV therapy.

Benzodiazepines increase fall, delirium, and dependence risk in older adults. Best practice is tapering protocols supported by prescriber and patient education, as recommended by Beers Criteria. Removing from formulary (B) is not practical. Barbiturates (C) are riskier. Restrictive dispensing (D) does not address safe discontinuation.

Phenytoin causes gingival hyperplasia due to fibroblast proliferation. Good oral hygiene reduces risk. Valproic acid, carbamazepine, and levetiracetam are not associated with this effect. Pharmacist counseling should emphasize dental care in patients on phenytoin.